Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ascendis Pharma A/S    ASND

ASCENDIS PHARMA A/S

(ASND)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ascendis Pharma A/S : quaterly earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/27/2019 | 09:15am EDT

The company will report its earnings for Q1 2019 on 05/30/2019. Generally, the company reports earnings in line with the consensus. In recent months, the 9 analysts from Thomson Reuters consensus have revised their EPS estimates upward.

Stocks mentioned in the article
ChangeLast1st jan.
ASCENDIS PHARMA A/S -1.46% 101.85 Delayed Quote.64.98%
THOMSON REUTERS CORP -0.84% 88.88 Delayed Quote.35.92%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASCENDIS PHARMA A/S
09/13ASCENDIS PHARMA A/S : Announces Presentations on Achondroplasia and TransCon CNP..
AQ
09/12ASCENDIS PHARMA A/S : Announces Presentations on Achondroplasia and TransCon&tra..
AQ
08/29Ascendis Pharma A/S Announces Three Investor Presentations in September
GL
08/28Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
GL
08/15ASCENDIS PHARMA A/S : Announces Second Quarter 2019 Financial Results and Busine..
AQ
08/14Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Busin..
GL
07/29Ascendis Pharma A/S Announces Participation in August Investor Conferences
GL
07/19ASCENDIS PHARMA A/S : Announces Filing of Investigational New Drug Application f..
AQ
07/18ASCENDIS PHARMA A/S : Announces Filing of Investigational New Drug (IND) Applica..
AQ
06/19Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare..
GL
More news
Financials (EUR)
Sales 2019 11,2 M
EBIT 2019 -223 M
Net income 2019 -228 M
Finance 2019 563 M
Yield 2019 -
P/E ratio 2019 -19,1x
P/E ratio 2020 -18,5x
EV / Sales2019 346x
EV / Sales2020 266x
Capitalization 4 438 M
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 143,65  €
Last Close Price 93,33  €
Spread / Highest target 84,8%
Spread / Average Target 53,9%
Spread / Lowest Target 31,7%
EPS Revisions
Managers
NameTitle
Jan Møller Mikkelsen President, Chief Executive Officer & Director
Michael Wolff Jensen Chairman, SVP & General Counsel
Neil T. Ringdahl Chief Operating Officer
Scott T. Smith Chief Financial Officer & Senior Vice President
Harald Rau Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASCENDIS PHARMA A/S64.98%4 914
GILEAD SCIENCES5.79%83 801
VERTEX PHARMACEUTICALS6.21%45 238
REGENERON PHARMACEUTICALS-22.86%31 527
GENMAB27.73%13 120
NEUROCRINE BIOSCIENCES, INC.42.01%9 287